Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exelixis (EXEL) PT Raised to $30 at Oppenheimer
August 6, 2021 10:36 AM EDTOppenheimer analyst Silvan Tuerkcan raised the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $27.00) while maintaining an Outperform rating.
The analyst commented, "EXEL provided 2Q financial results featuring record Cabo sales of $284.2M with continued uptake of nivo + cabo in 1L RCC following FDA... More
Exelixis (EXEL) Tops Q2 EPS by 30c
August 5, 2021 4:25 PM EDTExelixis (NASDAQ: EXEL) reported Q2 EPS of $0.37, $0.30 better than the analyst estimate of $0.07. Revenue for the quarter came in at $385.2 million versus the consensus estimate of $298.16 million.
GUIDANCE:
Exelixis sees FY2021 revenue of $1.3-1.4 billion, versus the consensus of $1.23... More
